Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980044/S063

SUPARTZ FX; VISCO-3

Seikagaku Corp. · Decision date Jul 22, 2025

FDA DECISIONP980044/S063

What did the FDA decide?

FDA records P980044/S063 as a supplement to PMA P980044, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 22, 2025.

FDA approval order statement

change to install an automated visual inspection (AVI) system to one line of the in-process inspection line used for the SUPARTZ product family
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Jul 22, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P980044/S063
Regulatory pathway
PMA supplement
Product code
MOZ
Decision code
OK30
Decision date
Jul 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

For the original device and its historical approval scope, see PMA P980044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980044/S063 received

    Application receipt date recorded by FDA.

  2. P980044/S063 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P980044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980044

Product / regulatory recordCompanyPathwayDecision dateSource
SUPARTZ FXP980044
Seikagaku Corp.PMA approvalJan 24, 2001FDA
SUPARTZ FXP980044/S064
Seikagaku Corp.PMA supplementAug 18, 2025FDA
Seikagaku Corp.PMA supplementDec 19, 2025FDA
SUPARTZ FXP980044/S068
Seikagaku Corp.PMA supplementAug 26, 2026FDA
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
GEL-ONEP080020/S057
Seikagaku Corp.PMA supplementAug 26, 2026FDA
Gelsyn-3P110005/S015
Ibsa Institut Biochimique SAPMA supplementJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Seikagaku Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records